Inogen (INGN) Addresses the Future of Respiratory Therapy - B. Riley Sees a Deeply Undervalued and Compelling Turnaround Story

Inogen Inc. (INGN) has demonstrated a robust financial performance in the first quarter of 2025. The company reported total revenue of $82.3 million, representing a 5.5% increase compared to the same period last year. Notably, there has been a significant reduction in the GAAP net loss, which decreased from $14.6 million last year to $6.2 million in the first quarter of 2025. With $122.5 million in cash and no outstanding debt as of March 31, 2025, Inogen showcases a solid balance sheet. For the second quarter of 2025, the company forecasts revenue...